A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Unecritinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 16 Aug 2020 Status changed from not yet recruiting to recruiting.
- 04 Jun 2020 New trial record